CRIS
CURIS INC
NASDAQ · Healthcare · Biotechnology · US
$1.08
+51.31%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$1.34
From 52W high−96.30%
Volume123.87M
Market cap$20.62M
P/E (TTM)—
P/S (TTM)4.8x
Div yield—
Key dataNov 4, 2026
Open
$1.34
From 52W high
−96.30%
Volume
123.87M
Market cap
$20.62M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.7x
P/E (TTM)
—
RSI (14)
57.3
MomentumView details →
1D Return
+51.31%
YTD Return
−96.01%
SummaryUpdated Jun 1, 2026
Curis, Inc. (NASDAQ:CRIS) is a biotechnology company founded in 2000 and headquartered in Lexington, Massachusetts. The company specializes in discovering and developing drug candidates for treating various human cancers, with a focus on blood cancers and solid tumors. Since going public in 2000, Curis has evolved from a broader drug discovery platform to concentrate primarily on oncology therapeutics, particularly through its lead compound <b>emavusertib</b>, which targets specific genetic mutations in cancer patients.
Similar companies
Latest newsMore news →
Curis entered into securities purchase agreements with existing healthcare-focused institutional investors for a private placement of 16,666,680 common shares or pre-funded warrants, plus warrants to purchase up to 16,666,680 shares, at an effective combined price of $0.51 per share or pre-funded warrant and accompanying warrant.19d agoCuris, Inc. priced a public offering of 3,733,334 shares of common stock (or pre-funded warrants) and warrants to purchase up to 3,733,334 shares of common stock at a combined price of $1.50 per share and accompanying warrant, raising approximately $5.6 million from healthcare-focused institutional investors.83d ago